trial · primary record
Semaglutide (Wegovy®)
Breast Cancer (Early Breast Cancer)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 32 |
| Primary completion | 2029-09 |
| Primary endpoint | Completion of the 26-week semaglutide treatment phase meeting all composite feasibility criteria |
| Registry ID | NCT07909889 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:32.188Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07909889
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Semaglutide · approval
- Semaglutide · compound